LTR Pharma (ASX:LTP) Total Receivables: A$0.51 Mil (As of Dec. 2025)


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.58
View Full Analysis

What is LTR Pharma Total Receivables?

LTR Pharma ASX:LTP +3.57% 15 Total Receivables is A$0.51 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100.

LTR Pharma's Total Receivables for the quarter that ended in Dec. 2025 was A$0.51 Mil.

LTR Pharma Total Receivables Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Total Receivables Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Total Receivables
0.00 0.00 0.00 0.27 0.25

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial 0.12 0.27 0.59 0.25 0.51
ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$0.51 Mil mean?
LTR Pharma (ASX:LTP) has a Total Receivables of A$0.51 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on LTR Pharma and its competitors.
Is LTR Pharma's Total Receivables too high?
LTR Pharma's current Total Receivables is A$0.51 Mil. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Total Receivables compare to VRTX and REGN?
LTR Pharma's Total Receivables of A$0.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on LTR Pharma and its competitors. LTR Pharma's current Total Receivables is A$0.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Total Receivables of A$0.51 Mil. The current Total Receivables is A$0.51 Mil. LTR Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Total Receivables is A$0.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.58
Price